Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

Blood

Volumn 91, Issue 3, 1998, Pages 756-763

  Slavin, Shimon ^a   Nagler, Arnon ^b   Naparstek, Ella ^b   Kapelushnik, Yossi ^b   Aker, Memet ^b   Cividalli, Gabriel ^b   Varadi, Gabor ^b   Kirschbaum, Mark ^b   Ackerstein, Aliza ^b   Samuel, Simcha ^b   Amar, Avraham ^b   Brautbar, Chaim ^b   Ben Tal, Ofira ^b   Eldor, Amiram ^b   Or, Reuven ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE PHOSPHATE; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032006125     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.3.756.756_756_763     Document Type: Article

References (28)

1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
2. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155, 1990
3. Moscovitch M, Slavin S: Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 132:997, 1984
4. Ben-Yosef R, Or R, Nagler A, Slavin S: Graft vs tumor and graft vs leukemia in patients with concurrent breast cancer and acute myelocytic leukemia. Lancet 348:1242, 1996
5. Passweg JR, Rowlings PA, Armitage JO, Gale RP, Pelz CJ, Sobocinski KA, Klein JP, Zhang M-J, Horowitz MM: Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America, in Cecka JM, Teraskaki PI (eds): Clinical Transplants, 1995. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1996, p 117
6. Slavin S, Or R, Naparstek E, Ackerstein A, Weiss L: Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 72:407a, 1988 (abstr, suppl 1)
7. Kolb HJ, de Witte T, Mittermuller J, Hertenstein B, Goldman JM, Ljungman P, Verdonck L, Holler E, Thalmaier K, Bartram C: Graft-versus-leukemia effect of donor buffy coat transfusions on recurrent leukemia after marrow transplantation. Blood 82:214a, 1993 (abstr, suppl 1)
8. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R: Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553, 1995
9. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87:2195, 1996
10. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Neumunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997
11. Slavin S, Weiss L, Morecki S, Weigensberg M: Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155, 1981
12. Cohen P, Vourka-Karussis U, Weiss L, Slavin S: Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor-and host-specific alloantigens. J Immunol 151:4803, 1993
13. Weiss L, Lubin I, Factorowich Y, Lapidot Z, Reich S, Reisner Y, Slavin S: Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2. Journal Immunol 153:2562, 1994
14. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S: Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 23:196, 1995
15. Pugatsch T, Oppenheim A, Slavin S: Improved single step PCR assay for sex identification post allogeneic sex-mismatched BMT. Bone Marrow Transplant 17:273, 1996
16. Nakamura Y, Leppert M, O'Connell P, Wolff R, Holm T, Culver M, Martin C, Fujimoto E, Hoff M, Kumlin E: Variable number of tandem repeats (VNTR) markers for uman gene mapping. Science 235:1616, 1987
17. Lin F, Kirkland MA, van Rhee FV, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NC: Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 18:1147, 1996
18. Nilsson SK, Dooner MS, Tiarks CY, Weier HU, Quesenberry PJ: Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 89:4013, 1997
19. Rao SS, Peters SO, Crittenden RB, Stewart FM, Ramshaw HS, Quesenberry PJ: Stem cell transplantation in the normal nonmyeloablated host: Relationship between cell dose, schedule, and engraftment. Exp Hematol 25:114, 1997
20. Weiss L, Reich S, Slavin S: Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 6:229, 1990
21. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, Tedone E, Frassoni F, Tong J, Marmont AM: Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77:1423, 1991
22. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar H, Hale G, Waldmann H, Steinberg SM, Slavin S: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506, 1995
23. Or R, Kapelushnik J, Naparstek E, Nagler A, Filon D, Oppenheim A, Amar A, Aker M, Samuel S, Slavin S: Second transplantation using allogeneic peripheral blood stem cells in a β-thalassaemia major patient featuring stable mixed chimerism. Br J Haematol 94:285, 1996
24. Slavin S, Strober S, Fuks Z, Kaplan HS: Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: Long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 146:34, 1977
25. Slavin S: Total lymphoid irradiation (TLI). Immunol Today 8:88, 1987
26. Ildstad ST, Sachs DH: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts and xenografts. Nature 307:168, 1984
27. Sykes M, Sachs DH: Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 9:23, 1988
28. Giralt S, Estey E, Albtar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531, 1997